Can Polpharma Biologics and Tuteur improve access to autoimmune disease biologics in Latin America?
LATAM autoimmune care needs cheaper biologics. Polpharma Biologics and Tuteur are betting a biosimilar deal can shift access.
Is Rein Therapeutics, Inc.’s Phase 2 execution enough to differentiate LTI-03 in IPF
Rein Therapeutics advances LTI-03 in Phase 2 IPF trial. Find out what this means for fibrosis drug competition and clinical development today.
Why the Veradermics hair loss trial is bigger than another aesthetics readout
Hair loss drugs are old, demand is huge, and Veradermics now faces the data test that could reset oral minoxidil’s commercial future.